Gritstone Oncology Inc (GRTSQ)

Currency in USD
0.003
0.000(0.00%)
Closed·
Showing Gritstone Oncology historical data. For real-time data please try another search
Day's Range
0.0030.003
52 wk Range
0.0011.040
Key Statistics
Prev. Close
-
Open
0.003
Day's Range
0.003-0.003
52 wk Range
0.001-1.04
Volume
-
Average Volume (3m)
688.25K
1-Year Change
-99.4%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Gritstone Oncology Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Gritstone Oncology Inc Company Profile

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Gritstone Oncology Inc SWOT Analysis


GRANITE's Promise
Explore Gritstone's pivotal GRANITE program for colorectal cancer, with key Phase 2 trial results expected in Q3 2024, potentially revolutionizing cancer treatment
Financial Outlook
Gritstone's $85.3M cash position supports operations through Q4 2024, with analysts setting a $5 price target amidst current market challenges
Beyond Cance
Delve into Gritstone's diverse pipeline, including a COVID-19 vaccine candidate and potential government funding, showcasing the company's versatile platform
Risk vs. Reward
Uncover the critical factors influencing Gritstone's future, from upcoming clinical data to funding needs, in a comprehensive SWOT analysis of this innovative biotech
Read full SWOT analysis

Gritstone Oncology Inc Earnings Call Summary for

  • GRANITE program shows positive PFS trend in colorectal cancer, with hazard ratios of 0.82 overall and 0.52 in high-risk patients
  • Q1 net loss of $40.4M; cash position of $52.8M after public offering and workforce reduction extends runway to Q4 2024
  • Mature PFS data expected Q3 2024; FDA discussions on phase three endpoints planned
  • BARDA talks ongoing for Phase 2b COVID-19 vaccine study; potential partnerships in sight
  • Company focuses on PFS improvement, particularly in low ctDNA patients; pursuing adjuvant indications for earlier stage trials
Last Updated: 11/05/2024, 15:14
Read Full Transcript

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-- / -0.18
Revenue / Forecast
-- / 1.70M
EPS Revisions
Last 90 days

GRTSQ Income Statement

People Also Watch

25.07
PFE
-0.28%
517.10
MSFT
-0.59%
767.37
META
-2.27%
231.49
AMZN
+0.20%
230.89
AAPL
-0.30%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.